Literature DB >> 26424501

The Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenoma.

Putipun Puataweepong1, Mantana Dhanachai2, Ake Hansasuta3, Somjai Dangprasert2, Thiti Swangsilpa2, Chomporn Sitathanee2, Chuleeporn Jiarpinitnun2, Patamintita Vitoonpanich2, Pornpan Yongvithisatid4.   

Abstract

Stereotactic radiation technique including single fraction radiosurgery and conventional fractionated stereotactic radiotherapy is widely reported as an effective treatment of pituitary adenomas. Because of the restricted radiation tolerance dose of the optic pathway, single fraction radiosurgery has been accepted for small tumor located far away from the optic apparatus, while fractionated stereotactic radiotherapy may be suitable for larger tumor located close to the optic pathway. More recently, hypofractionated stereotactic radiotherapy has become an alternative treatment option that provides high rate of tumor control and visual preservation for the perioptic lesions within 2 to 3 mm of the optic pathway. The objective of the study was to analyze the clinical outcomes of perioptic pituitary adenomas treated with hypofractionated stereotactic radiotherapy. From 2009 to 2012, 40 patients with perioptic pituitary adenoma were treated with CyberKnife robotic radiosurgery. The median tumor volume was 3.35 cm3 (range, 0.82-25.86 cm3). The median prescribed dose was 25 Gy (range, 20-28 Gy) in 5 fractions (range, 3-5). After the median follow-up time of 38.5 months (range, 14-71 months), 1 (2.5%) patient with prolactinoma had tumor enlargement, 31 (77.5%) were stable, and the remaining 8 (20%) tumors were smaller in size. No patient's vision deteriorated after hypofractionated stereotactic radiotherapy. Hormone normalization was observed in 7 (54%) of 13 patients. No newly developed hypopituitarism was detected in our study. These data confirmed that hypofractionated stereotactic radiotherapy achieved high rates of tumor control and visual preservation. Because of the shorter duration of treatment, it may be preferable to use hypofractionated stereotactic radiotherapy over fractionated stereotactic radiotherapy for selected pituitary adenomas immediately adjacent to the optic apparatus.
© The Author(s) 2015.

Entities:  

Keywords:  CyberKnife; hypofractionated stereotactic radiosurgery; perioptic; pituitary adenoma; robotic radiosurgery

Mesh:

Year:  2015        PMID: 26424501     DOI: 10.1177/1533034615607113

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  8 in total

Review 1.  Updates in outcomes of stereotactic radiation therapy in acromegaly.

Authors:  Monica Livia Gheorghiu
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

2.  Safety and efficacy of multisession gamma knife radiosurgery for residual or recurrent pituitary adenomas.

Authors:  Luigi Albano; Marco Losa; Francesco Nadin; Lina Raffaella Barzaghi; Veronica Parisi; Antonella Del Vecchio; Angelo Bolognesi; Pietro Mortini
Journal:  Endocrine       Date:  2019-02-23       Impact factor: 3.633

3.  Clinical outcomes of perioptic tumors treated with hypofractionated stereotactic radiotherapy using CyberKnife® stereotactic radiosurgery.

Authors:  Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Somjai Dangprasert; Chomporn Sitathanee; Rawee Ruangkanchanasetr; Pornpan Yongvithisatid
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

4.  Significance of surgical management for cystic prolactinoma.

Authors:  Toshihiro Ogiwara; Tetsuyoshi Horiuchi; Alhusain Nagm; Tetsuya Goto; Kazuhiro Hongo
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

Review 5.  Management of nonfunctioning pituitary tumors: radiotherapy.

Authors:  Giuseppe Minniti; John Flickinger; Barbara Tolu; Sergio Paolini
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 6.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

Review 7.  Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.

Authors:  Michael T Milano; Jimm Grimm; Scott G Soltys; Ellen Yorke; Vitali Moiseenko; Wolfgang A Tomé; Arjun Sahgal; Jinyu Xue; Lijun Ma; Timothy D Solberg; John P Kirkpatrick; Louis S Constine; John C Flickinger; Lawrence B Marks; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-01-31       Impact factor: 8.013

8.  Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.

Authors:  Rupesh Kotecha; Arjun Sahgal; Muni Rubens; Antonio De Salles; Laura Fariselli; Bruce E Pollock; Marc Levivier; Lijun Ma; Ian Paddick; Jean Regis; Jason Sheehan; Shoji Yomo; John H Suh
Journal:  Neuro Oncol       Date:  2020-03-05       Impact factor: 12.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.